01673nas a2200337   4500000000100000008004100001260001700042653001500059653001000074653001600084653001100100653003000111653001100141653002600152653002100178653001200199653000900211653001600220100001500236700001200251700001400263700001100277700001400288700001400302245007400316300001100390490000700401050003200408520088100440022001401321       1985                            d  c1985 Apr-Jun10aAdolescent10aAdult10aClofazimine10aFemale10aGastrointestinal Diseases10aHumans10aIntestinal Absorption10aIntestine, Small10aleprosy10aMale10aMiddle Aged1 aBhasin D K1 aKumar B1 aBroor S L1 aKaur S1 aMalik A M1 aMehra S K00aEffect of clofazimine: detailed studies of small intestine functions.  a364-720 v57  aInfolep Library - available3 a<p>Twenty one patients of leprosy were studied for gastrointestinal symptoms and submitted to detailed intestinal absorption tests and jejunal biopsy before and after the institution of Clofazimine therapy. Fifteen patients were administered 100 mg orally daily for 3 months, while six patients with ENL received 300 mg of the drug for 6 weeks initially and then 100 mg daily. Mild diarrhoea and abdominal symptoms occurred in four patients, fecal fat excretion increased in one patient but Schilling's and d-Xylose tests did not alter. No significant changes were produced by Clofazimine therapy in jejunal mucosa. Clofazimine crystals were seen in the lamina properia of one patient, the overlying mucosa was normal. No correlation was found between the abnormality in mucosal pattern, crystal deposition, absorption parameters or symptomatology and doses of drug taken.</p>  a0254-9395